Startup Ideas AI

Aitia harnesses Causal AI, Multi-Omics data and Gemini Digital Twins to discover the next generation of breakthrough drugs.

We discover novel drug-like small molecules with optimized properties for defined targets

BenevolentAI (Euronext Amsterdam: BAI) is a company that applies advanced AI to accelerate biopharma drug discovery. Their next-generation platform targets the complex decisions that drive R&D, providing life science intelligence. They build technology in the service of science, bringing together science and technology teams to push AI and machine learning to new limits. They leverage their knowledge graph and proprietary ontologies to support scientists and executives in leveraging cutting-edge AI with confidence and precision.

floatz AI for Drug Discovery helps surface high-potential drug targets grounded in human genetics, expression patterns, and biological pathways, built for translational success. It integrates human genetics, tissue expression, and pathway analysis to map billions of concepts and identify targets with real translational potential, delivering 3 clinically-relevant targets in 14 days.